A new global study reveals that a single dose of the RSV vaccine for older adults—Arexvy, developed by GSK—can protect people aged 60 and older from severe RSV-related lung infections for up to three consecutive seasons.
RSV Risks for Older Adults
Respiratory syncytial virus (RSV) poses a serious threat to adults over 60, especially those with chronic health conditions like asthma, heart disease, or COPD. Each RSV season leads to thousands of hospitalizations among older adults, making effective prevention critical.
Why the RSV Vaccine for Older Adults Is a Breakthrough
According to a study published in The Lancet, the Phase 3 AReSVi-006 trial found that one dose of the RSVPreF3 OA vaccine (Arexvy) significantly reduced the risk of respiratory illness:
- 62.9% lower risk of RSV-related lower respiratory tract disease (RSV-LRTD)
- 67.4% lower risk of severe RSV-LRTD
- 51.1% reduction in RSV-related acute respiratory illness
The vaccine provided these benefits over a median 30.6-month follow-up, covering three full RSV seasons.
Study Scope and Global Reach
The Phase 3 trial included over 24,000 adults aged 60+ across 17 countries. According to GSK, Arexvy showed consistent efficacy among participants regardless of age or pre-existing conditions.
Durable Effectiveness in the Real World
Effectiveness remained strong across three RSV seasons. While protection against severe disease was highest in the first year (94.1%), it remained at 43.3% in year three, as reported by Reuters.
Expert Insight and Future Outlook
Health experts say these results mark a significant advancement in RSV prevention. As News-Medical.net notes, the RSV vaccine for older adults could dramatically reduce hospitalizations and become part of routine care during RSV season.
For more details, refer to the full clinical report in The Lancet and GSK’s official announcement.
Medical Disclaimer: This content is for informational purposes only. It is not intended as medical advice. Please consult a healthcare provider before making health decisions.
Explore More :
https://innovatemed.org
